Amazon ’s RxPass Doesn’t Yet Really Compete With Mark Cuban’s Cost Plus Drug Company

Amazon is adding RxPass to its pharmacy footprint. Purportedly, it ’s competing with Mark Cuban’s Cost Plus Drug Company (MCCPDC). But, limitations suggest it isn’t yet a real competitor.

Source: Forbes.com Healthcare News - February 3, 2023 Category: Pharmaceuticals Authors: Joshua Cohen, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & Source Type: news